Israel - hebraisk - Ministry of Health

pfizer pharmaceuticals israel ltd - etanercept - תמיסה להזרקה - etanercept 50 mg/ml - etanercept - etanercept - * rheumatoid arthritis:enbrel is indicated for the treatment of active rhematoid arthritis in adults when the response to disease-modifying antirheumatic drugs (dmards) including methotrexate (unless contraindicated) has been inadequate.. enbrel can be used in combination with methotrexate in patients who do not respond adequately to methotrexate alone. reducing signs and symptoms and inhibiting the progression of structural damage in patients with moderately to severely active rheumatoid arthritis.enbrel, alone or in combination with methotrexate, has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function.* polyarticular juvenile idiopathic arthritis: treatment of active polyarticular juvenile idiopathic arthritis in children and adolescents from the age of 2 years who have had an inadequate response to, or who have proved intolerant of, methotrexate. enbrel has not been studied in children aged less than 2 years.* psoriatic arthritistreatment of ac

Israel - hebraisk - Ministry of Health

bristol, myers squibb (israel) limited, israel - abatacept - אבקה להכנת תמיסה מרוכזת לעירוי - abatacept 250 mg - abatacept - abatacept - orencia in combination with methotrexate is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who responded inadequately to previous therapy with one or more disease modifying anti rheumatic drugs (dmards) including methotrexate (mtx) or a tnf-alpha inhibitor.a reduction in the progression of joint damage and improvement of physical function have been demonstrated during combination treatment with abatacept and methotrexate.polyarticular juvenile idiopathic arthritis:orencia in combination with methotrexate is indicated for the treatment of moderate to severe active polyarticular juvenile idiopathic arthritis (jia) in paediatric patients 6 years of age and older who have had an insufficient response to other dmards including at least one tnf inhibitor. orencia has not been studied in children under 6 years old.

Israel - hebraisk - Ministry of Health

neopharm (israel)1996 ltd - adalimumab - תמיסה להזרקה - adalimumab 50 mg/ml - adalimumab

Israel - hebraisk - Ministry of Health

padagis israel agencies ltd, israel - rituximab - תרכיז להכנת תמיסה לאינפוזיה - rituximab 10 mg/ml - rituximab

Israel - hebraisk - Ministry of Health

amgen europe b.v. - adalimumab - תמיסה להזרקה - adalimumab 50 mg / 1 ml - adalimumab

Israel - hebraisk - Ministry of Health

novartis israel ltd - adalimumab - תמיסה להזרקה - adalimumab 50 mg/ml - adalimumab

Israel - hebraisk - Ministry of Health

glaxo smith kline (israel) ltd - belimumab - אבקה להכנת תמיסה מרוכזת לעירוי - belimumab 120 mg - belimumab - belimumab - benlysta is indicated as add-on therapy in adult patients with active, autoantibody-positive systemic lupus erythematosus (sle) with a high degree of disease activity (e.g positive anti dsdna and low complement) despite standard therapy.

Israel - hebraisk - Ministry of Health

glaxo smith kline (israel) ltd - belimumab - אבקה להכנת תמיסה מרוכזת לעירוי - belimumab 400 mg - belimumab - belimumab - benlysta is indicated as add-on therapy in adult patients with active, autoantibody-positive systemic lupus erythematosus (sle) with a high degree of disease activity (e.g positive anti dsdna and low complement) despite standard therapy.

Israel - hebraisk - Ministry of Health

megapharm ltd - anakinra - תמיסה להזרקה - anakinra 150 mg/ml - anakinra - anakinra - kineret is indicated for the treatment of the signs and symptoms of rheumatoid arthritis in combination with methotrexate, in patients with an inadequate response to methotrexate alone.

Israel - hebraisk - Ministry of Health

glaxo smith kline (israel) ltd - belimumab - תמיסה להזרקה - belimumab 200 mg / 1 ml - belimumab